Skip to main content
. 2022 Jun 15;9:1316–1324. doi: 10.1016/j.toxrep.2022.06.008

Table 7.

Summary of results from the MTT viability assay for 1R6F and smokeless products extracts in the EpiGingival™ 3D Tissue Model (4-h and extended overnight Treatment). Values represent average viability calculated from 3 wells per tissue at a given concentration, (duplicate tissues were tested).

Values represent average viability calculated from 3 wells per tissue at a given concentration, (duplicate tissues were tested)
Product Dose Level
(%, v/v) or
(%,w/v) SP
Average
Viability (%)
4-h Treatment
(Initial Irritation assay)
Average
Viability (%)
4-h Treatment
(Confirmatory irritation assay)
Average
Viability (%)
18-h Treatment
(Initial Irritation assay)
Average
Viability (%)
18-h Treatment
(Confirmatory irritation assay)
1R6F 0.625 102 97 108 113
1.25 135 95 103 112
2.50 101 91 99 110
5.00 98 100 100 111
VC 100 µL 100 100 100 100
SLS 0.5 or 0.15 24 28 6 18
NP1 M 6 mg 3.75 97 98 103 99
7.5 92 102 107 93
15 97 93 97 126
30 101 98 86 76
VC 100 µL 100 100 100 100
SLS 0.5 or 0.15 15 31 21 14
NP1 M 9 mg 3.75 101 91 106 93
7.5 98 88 107 83
15 100 91 95 83
30 102 86 88 92
VC 100 µL 100 100 100 100
SLS 0.5 or 0.15 29 22 8.4 5
NP1 SM 11.2 mg 3.75 97 105 95 97
7.5 102 94 95 104
15 97 91 93 81
30 81 81 79 75
VC 100 µL 100 100 100 100
SLS 0.5 or 0.15 20 27 12 9

VC = 5 % Ethanol in Phosphate Buffered Saline (1R6F only) or VC = Vehicle Control; Complete Artificial Saliva

SLS - Sodium Lauryl Sulfate (%, w/v).